PURPOSE: To present our preliminary observations on the late @entity137 and quality of life (QOL) of @entity1 treated with short-course intensity-modulated radiotherapy (SCIM-RT). METHODS AND MATERIALS: Fifty-one @entity1 were treated with SCIM-RT at the Cleveland Clinic Foundation between October 1998 and May 1999. The technique consisted of intensity-modulated radiotherapy using 5 static fields (anterior, 2 laterals, and 2 anterior obliques). Inverse plans were generated by the Corvus treatment-planning system. The treatment delivery was performed with a dynamic multileaf collimator. A total of 70.0 Gy was prescribed in all cases at 2.5 Gy per fraction to be delivered in 28 fractions over 5 and a half weeks. The location of the prostate gland was verified and adjusted daily with the BAT transabdominal ultrasound system. The median follow-up was 18 months (range: 11 to 26 months). The Radiation Therapy Oncology Group (RTOG) scales were used to evaluate late @entity137 . The Expanded @entity263 Index Composite (EPIC) was used to evaluate QOL. A total of 24 @entity1 completed the EPIC questionnaire at approximately 2 years after therapy (median time from treatment to questionnaire administration: 24 months; range: 21 to 26 months). The results from the EPIC questionnaires were compared to scores from 46 @entity1 treated during the same time period with conformal radiotherapy (CRT) to 78 Gy at 2 Gy per fraction. RESULTS: The dose was prescribed to an isodose line ranging from 82.0% to 90.0% (mean: 87.2%). The range of the individual prostate mean doses was 73.5 to 78.5 Gy (average: 75.3 Gy). To date, only 1 @entity1 had Grade 1 late urinary @entity137 . To date, only 4 @entity1 had Grade 1 late @entity137 . No Grade 2 or 3 late urinary or rectal complications have occurred. The actuarial rectal bleeding rate observed at 18 months was 7%. There were no differences in scores from the urinary, bowel, hormonal, and overall QOL domains between SCIM-RT @entity1 and @entity1 treated with CRT. The overall physical and mental QOL scores were also nearly identical to scores reported for the general U.S. population. CONCLUSION: Preliminary late @entity137 results up to 2 years after SCIM-RT are encouraging, with a median follow-up of 18 months (range 11 to 26 months). Late @entity137 assessed by the physicians using RTOG late @entity137 scores has been excellent. QOL reported by the @entity1 using the EPIC questionnaire reveals no difference between @entity1 treated with high-dose CRT at standard fractionation and @entity1 treated with SCIM-RT. SCIM-RT is an alternative method of dose escalation in the treatment of @entity263 . The proposed schedule significantly increases convenience to @entity1 due to the decrease in overall treatment time.

Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for @entity263 : preliminary results on late XXXX and quality of life.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'rectal toxicity'] @entity263 :: ('MESH:D011471', 'Disease') :: ['localized prostate cancer', 'Prostate Cancer']
@entity137 :: (MESH:D064420,Disease) :: ['toxicity']
